The extraordinary success of incretin-based glucose-lowering medications in type 2 diabetes,, which are mainly based on properties of the incretin hormone glucagon-like peptide-1 (GLP-1) [1], has reinforced interest in the physiology and pathophysiology of incretin hormones more generally. Here, GLP1R is linked to type 2 diabetes mellitus.